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Background: Langerin is a receptor in the immune system that binds sugars on pathogens.
Results:The effects of genetic variations that cause changes in the sugar-binding site of human langerin have been investigated.
Conclusion: Two common, linked, variations in the gene for human langerin change sugar specificity of langerin.
Significance: Individuals with variant forms of langerin may have altered susceptibility to pathogenic microorganisms.
Langerin, a C-type lectin on Langerhans cells, mediates car-
bohydrate-dependent uptake of pathogens in the first step of
antigen presentation to the adaptive immune system. Langerin
binds a diverse range of carbohydrates including high mannose
structures, fucosylated blood group antigens, and glycans with
terminal 6-sulfated galactose. Mutagenesis and quantitative
binding assays indicate that salt bridges between the sulfate
group and two lysine residues compensate for the nonoptimal
binding of galactose at the primary Ca2 site. A commonly
occurring single nucleotide polymorphism (SNP) in human lan-
gerin results in change of one of these lysine residues, Lys-313,
to isoleucine. Glycan array screening reveals that this amino
acid change abolishes binding to oligosaccharides with terminal
6SO4-Gal and enhances binding to oligosaccharides with termi-
nal GlcNAc residues. Structural analysis shows that enhanced
binding to GlcNAc may result from Ile-313 packing against the
N-acetyl group. The K313I polymorphism is tightly linked to
another SNP that results in the change N288D, which reduces
affinity for glycan ligands by destabilizing the Ca2-binding
site. Langerin with Asp-288 and Ile-313 shows no binding
to 6SO4-Gal-terminated glycans and increased binding to
GlcNAc-terminated structures, but overall decreased binding to
glycans. Altered langerin function in individuals with the linked
N288D and K313I polymorphisms may affect susceptibility to
infection by microorganisms.
Langerin (CD207), a C-type lectin of Langerhans cells, can
act as a pathogen receptor by binding to surface glycoconju-
gates of microorganisms (1–3). Pathogens bound by langerin
includeMycobacterium leprae (4), viruses such as HIV, herpes
simplex virus 2, and measles virus (5–7), and fungi including
Malassezia furfur and Candida species (8, 9). Langerin medi-
ates internalization of glycoconjugates into Birbeck granules,
which are subdomains of the endosomal compartment unique
to Langerhans cells, as the first step in antigen processing and
presentation, the main function of Langerhans cells (1, 7, 10,
11). Langerin protects against HIV infection by internalizing
the virus to Birbeck granules for degradation (5, 12).
The extracellular portion of langerin contains a C-type car-
bohydrate recognition domain (CRD)2 that binds sugars and a
neck region that mediates formation of trimers stabilized by a
coiled-coil of -helices (13). Langerin binds to a diverse set of
glycan ligands including high mannose structures, -glucans,
and fucosylated blood group antigens (8, 9, 13–15). As in
other C-type lectins, the CRD of langerin contains a primary
Ca2-dependent sugar-binding site where Ca2 forms direct
coordination bonds with two vicinal hydroxyl groups of a
monosaccharide (16–18). Crystal structures of langerin-ligand
complexes show that specificity for high mannose oligosaccha-
rides, -glucans, and the blood group B trisaccharide results
from binding of a single mannose, glucose, or fucose residue to
the Ca2 at the primary sugar-binding site and a small number
of favorable contacts with other portions of the oligosaccharide
ligands beyond themonosaccharide in the primary binding site
(18).
Uniquely for aC-type lectinwith the characteristicmannose-
type binding motif Glu-Pro-Asn at the primary Ca2- and sug-
ar-binding site (19, 20), langerin can also bind galactose-type
ligands. Langerin binds glycans with terminal 6-sulfated galac-
tose but not those with terminal 3-sulfated galactose or nonsul-
fated galactosides (9, 14, 15). The equatorial 3- and axial 4-OH
groups of galactose ligate to the Ca2 at the primary sugar-
binding site with salt bridges formed between two lysine resi-
dues and the sulfate group (see Fig. 1) (18). The nonoptimal
Ca2 ligation of galactose at the primary sugar-binding site
appears to be compensated by the charge-charge interactions
between the sulfate group and the two lysine residues. Glycans
with terminal 6SO4-Gal are not typical markers of pathogens.
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However, an endogenous ligand, keratan sulfate, containing
repeating 6SO4-Gal1-4GlcNAc units is bound by langerin,
suggesting a possible role for 6SO4-Gal recognition by langerin
in cell adhesion (9). Recently, other glycosaminoglycans, espe-
cially heparin, have been shown to interact with langerin, but
this binding is Ca2-independent and appears to be due to
charge-charge interactions with part of the trimeric neck
region, not due to binding to the CRD (21).
The human langerin gene contains many single nucleotide
polymorphisms (SNPs) including some that cause amino acid
changes in the CRD and affect sugar binding activity (22). The
studies described here characterize the effects of a polymor-
phism that changes Lys-313, one of the amino acid residues
critical for binding 6SO4-Gal-terminating glycans, to isoleu-
cine, which is linked to another SNP that changes Asn-288 to
Asp. A combination of mutagenesis, glycan array screening,
and structural studies shows that the K313I change alters the
specificity of langerin for glycans in an unexpected way, not
only abolishing binding to 6SO4-Gal-containing ligands, but
also causing enhanced binding to glycans with terminal
GlcNAc.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—Amino acid changes
corresponding to the polymorphisms in the CRD of human
langerin and other mutations were introduced into the human
langerin cDNA using synthetic oligonucleotides. Expression and
purification of wild type and mutant forms of the langerin CRD
and of a trimeric fragment of the extracellular domain contain-
ing the CRD plus part of the neck region (truncated langerin)
were produced using bacterial expression systems as described
previously (13, 15).
Analysis of Ligand Binding—Specificity of wild type and
mutant langerin for 6SO4-Gal and mannose was determined
using a solid-phase binding assay with truncated langerin
immobilized to polystyrene wells (13). Fluorescein-labeled
truncated langerin, prepared as described previously (15), was
used to probe version 5.1 of the glycan array following the
standard procedure of Core H of the Consortium for Func-
tional Glycomics.
Analysis of Langerin SNPs in Genomic DNA—Human
genomic DNA samples were obtained from the European Col-
lection of Cell Cultures (Salisbury, UK). Part of the langerin
gene containing exons 5 and 6 was amplified from human
genomic DNA samples by PCR using forward primer 5-gctc-
caagtgtggccgcacctctg-3 and reverse primer 5-gagctcaaagagt-
gagcttgggag-3. Amplified DNA was sequenced on an ABI
Prism 310 genetic analyzer. For analysis of individual alleles
from genomic DNA samples heterozygous for langerin SNPs,
PCR products were cloned into plasmid CR II TOPO using the
Topo cloning kit (Invitrogen), and clones were sequenced.
Crystallization and Data Collection—The crystals of lan-
gerin CRD, langerin-I313 CRD, and langerin-D288/I313 CRD
complexed with carbohydrate ligands were obtained by hang-
ing-drop vapor diffusion, using amixture of 1.5–2l of protein-
carbohydrate complex and 0.75–1 l of reservoir solution in a
drop. Crystals were grown at 22 °C from a protein solution
comprising 2.3–4.0mg/ml langerin, 2.5mMCaCl2, 10–100mM
Tris (pH 8.0), 25 mM NaCl with excess of sugar, as follows.
GlcNAc (Sigma) or-Me-GlcNAc (Sigma) was added at 50mM
to form complexes with langerin-I313 CRD or langerin-D288/
I313CRD.GlcNAc (50mM) or-Me-GlcNAc (60mM)was added
to form the wild type langerin CRD complexes. -Me-Man
(Sigma) at 50 mM was used to form the complex with langerin-
D288/I313 CRD. Trisaccharides GlcNAc1-3Gal1-4Glc-
CH2CH2N3 and GlcNAc1-3Gal1-4GlcNAc-CH2CH2N3
(compounds TR54 and TR55 fromCore D of the Consortium for
FunctionalGlycomics)wereadded to theprotein solutionat a final
concentration of 15 mM. The reservoir solution contained 0.1 M
HEPES (pH 7.0), 0.1–0.2 MMgCl2, and 20–35% polyethylene gly-
col 3350.All crystals, except for the complex of langerinCRDwith
trisaccharide TR54, were transferred to perfluoropolyether (PFO-
XR75; Lancaster Synthesis) before being frozen in liquid nitrogen
for data collection. The crystal of langerin CRDwith trisaccharide
TR54was frozendirectly fromthe crystallizationdrop.Diffraction
data for the complexes of langerin CRD and langerin-I313 CRD
with-Me-GlcNAcorGlcNAcweremeasured at 100Konbeam-
line 5.0.3 at the Advanced Light Source. Diffraction data for the
complexes of langerin CRD, langerin-I313 CRD, and langerin-
D288/I313CRDwith trisaccharide TR54 or TR55 and for the lan-
gerin-D288/I313 CRD with -Me-GlcNAc and -Me-Man were
measured at 100 K on beamline 11-1 at the Stanford Synchrotron
Radiation Lightsource. Data were processed with MOSFLM or
XSD and scaled with SCALA.
Structure Determination—The crystals belonged to space
group P42 with unit cell parameters similar to those published
for other langerin CRD complexes, allowing structure solution
directly by rigid body refinement (18). The model from Protein
Data Bank entry 3P5G, without the blood group B trisaccharide
or water molecules, was used as the starting model for the
refinement of the complex of langerin. For all the data sets, the
same reflections were marked as the test set as in the data for
langerinwith blood group B trisaccharide. The crystallographic
asymmetric unit contains four copies of the CRD.Model build-
ing and refinement were performed with Coot and PHENIX
(23, 24). Refinement included individual positional and isotro-
pic temperature factor refinement for all atoms, except in some
structures where theCa2was refinedwith an anisotropic tem-
perature factor. All models start at residue 196, 197, or 198 and
end at residue 324 or 325. The sugar directly bound to the
principal Ca2 is visible in all copies. The second and third
sugars of the trisaccharides were added to themodel when they
were clearly visible in the electron density maps.
RESULTS
A Naturally Occurring Polymorphism in Langerin That
Affects Binding to 6SO4-Gal—Several single nucleotide poly-
morphisms in the human langerin gene that cause nonsynony-
mous amino acid changes have been reported in the National
Center for Biotechnology Information (NCBI) SNP database
(www.ncbi.nlm.nih.gov/snp). The effects of three of these
amino acid changes in the CRD on langerin function were pre-
viously investigated: A278V (SNP database cluster identifica-
tion rs741326), N288D (SNP database cluster identification
rs13383830), and A300P (SNP database cluster identification
rs2080391) (22). Subsequent to the earlier studies, SNP
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rs57302492, which results in the change of lysine at position
313 to isoleucine, has been identified. The crystal structure of
the CRD of langerin in complex with 6SO4-Gal1-4GlcNAc
shows that Lys-313 is one of two lysine residues that form salt
bridges with the SO4 group of 6SO4-Gal, making it likely that
the K313I change would impair binding to 6SO4-Gal-contain-
ing ligands (18).
To place the impact of this novel polymorphism in context,
mutagenesis studies on residues in the langerin 6SO4-Gal-
binding site were conducted to establish the importance of the
interactions observed in the crystal structure. The interactions
with the 3- and 4-OH groups of the galactose moiety, through
the principal Ca2 ion, are common to the C-type CRDs (16).
Interactions unique to the langerin-binding site for 6SO4-Gal
include the salt bridges between the SO4 group andLys-313 and
Lys-299 and packing of Ala-289 against the galactose ring (Fig.
1) (18). This packing results from tipping of galactose relative to
mannose bound at the same site, reflecting the different geom-
etry of the 3- and 4-OH groups of galactose as compared with
mannose.
The contributions of Lys-313, Lys-299, and Ala-289 to bind-
ing of 6SO4-Gal were assessed by quantifying the impact of
mutations at these positions in a trimeric fragment of the extra-
cellular domain of langerin, designated truncated langerin (15).
Comparing the inhibition constants formannose and 6SO4-Gal
indicates that wild type langerin has similar affinities for these
two sugars with the KI for 6SO4-Gal about 1.4 times that of
mannose (Table 1 and Fig. 2). Mutation of either Lys-313 or
Lys-299 to alanine significantly reduces affinity for 6SO4-Gal
without affectingmannose binding, andmutation of both lysine
residues to alanine reduces binding of 6SO4-Gal to a weak level
similar to that seen for galactose (Table 1 and Fig. 2). This resid-
ual level of binding reflects the fact that free galactose mono-
saccharide can bind weakly at the principal Ca2 of langerin
through interaction with the 2-OH group and the anomeric
hydroxyl group (13). Such binding is an artifact because the
anomeric hydroxyl would not be available in an oligosaccharide
ligand. The loss of affinity for 6SO4-Gal in the double mutant
supports the hypothesis that the salt bridges formed between
the sulfate group of 6SO4-Gal and the two lysine side chains are
necessary to compensate for the unfavorable orientation of
galactose binding. Mutation of Ala-289 to serine resulted in a
small reduction in affinity for 6SO4-Gal relative to mannose
with KI,Man/KI,Gal 6-SO4 of 0.87, indicating that interaction of
Ala-289 with the pyranose ring of galactose may also make a
small contribution to 6SO4-Gal binding.
Mutation of Lys-313 to isoleucine, mimicking the naturally
occurring variation, has a similar effect to the K313Amutation,
with a 4-fold decrease in the KI for 6SO4-Gal as compared with
wild type (Table 1 and Fig. 2). Thus, it seems likely that langerin
function would be altered in individuals with the Ile-313 form
of langerin.
Linkage of the K313I Polymorphism to Another Polymor-
phism, N288D—Genomic DNA samples from several different
populations were analyzed to assess the frequency of the K313I
polymorphism. DNA corresponding to exon 6 of the langerin
gene, which encodes amino acids 280 to the C terminus, was
amplified by PCR and sequenced directly. Several individuals
FIGURE 1. Mechanism of 6SO4-Gal binding by langerin. Langerin CRD
bound to 6SO4-Gal1-4GlcNAc (18). The protein is shown in green, Ca
2 is in
orange, oxygen atoms are red, nitrogen atoms are blue, and the sulfur atom is
gold.
TABLE 1
Binding of 6SO4-Gal to langerin
Relative inhibition constants for mannose, 6SO4-Gal, and galactose were deter-
mined in binding competition assays in which the reporter ligand 125I-labeled man-
nose-bovine serum albumin was bound to langerin immobilized in polystyrene
wells. KI values represent mean  S.D. of two independent assays performed in
duplicate.
Mutant
langerin KI,Man KI,6SO4-Gal KI,Gal
KI,Man/
KI, 6SO4-Gal
mM mM mM
Wild type 4.4 0.1 3.1 0.4 27.6 0.1 1.44
K299A 4.8 0.1 7.8 0.4 0.62
K313A 3.8 0.6 6.7 0.9 0.56
K299A/K313A 4.1 0.4 21.8 0.8 16.3 0.7 0.19
K313I 4.2 0.1 10.2 0.4 0.41
FIGURE2.EffectofLys-299andLys-313mutationsonbindingof6SO4-Gal
to langerin. Inhibition of binding of the reporter ligand 125I-labeled man-
nose-BSA to langerin immobilized in polystyrene wells by mannose or 6SO4-
Gal is demonstrated. Results are representative of two experiments per-
formed in duplicate.
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heterozygous for the Ile-313 variant were identified but no
homozygotes (Fig. 3 and Table 2). Exon 6 of the langerin gene
also contains two other SNPs that affect langerin function,
causing the changes N288D and A300P, so it was possible to
look for these changes at the same time. None of the individuals
had proline at position 300, confirming that this is a rare
change. However, all of the individuals heterozygous for the
amino acid at position 313 were also heterozygous for the
N288D polymorphism. No individuals homozygous for Asp at
position 288 were found. To determine whether the codons
specifying Ile-313 and Asp-288 were present on the same chro-
mosome in each of the heterozygous individuals, the PCRprod-
ucts obtained were cloned, and several independent clones
were sequenced. Only two types of clones with respect to the
polymorphisms at positions 288 and 313 were found, one cod-
ing for Asn-288 and Lys-313, and another coding for Asp-288
and Ile-313. These results indicate that the two polymor-
phisms are linked, with the common allele encoding Asn-288
and Lys-313 and the variant form encoding Asp-288 and
Ile-313. The frequency of the minor allele was highest in the
African samples.
Frequency data are available for these two polymorphisms in
the SNP database (www.ncbi.nlm.nih.gov/snp). In all popula-
tions studied, the allele frequencies for the K313I polymor-
phismare identical to those for theN288Dpolymorphism.Data
from the 1000 Genomes Phase 1 study are consistent with the
PCR data showing that the K313I polymorphism and the
N288D polymorphism are linked. The minor allele frequency
for each of the two polymorphisms is 10.7%. In each case, the
minor allele was seen 233 times in the population of 1092 peo-
ple or 2184 chromosomes. For each polymorphism, 12 of the
1092 individuals are homozygous for the minor allele. In every
case where an individual is homozygous for Ile at position 313,
they are also homozygous for Asp at position 288, and individ-
FIGURE3.Genomicanalysisof langerinpolymorphisms.A, exon structureof the langeringene. Thepale green circle indicates the regionof thegene thatwas
sequenced. B, sequence of the coding region of exon 6 showing the positions of N288D and K313I polymorphisms. C, sequence of parts of exon 6 for an
individual heterozygous for N288D and K313I. D, sequence of allele 1 from the heterozygous individual showing Asn-288 and Lys-313. E, sequence of allele 2
from the heterozygous individual showing Asp-288 and Ile-313.
TABLE 2
Frequencies of K313I andN288Dpolymorphisms determined by sequencing of exon 6 of the langerin gene fromhumangenomic DNA samples
Population
Number of
samples
Position 313 Position 288
AAA/AAA
(Lys/Lys)
AAA/ATA
(Lys/Ile)
ATA/ATA
(Ile/Ile)
AAT/AAT
(Asn/Asn)
AAT/GAT
(Asn/Asp)
GAT/GAT
(Asp/Asp)
Black African 20 15 5 0 15 5 0
Japanese 9 8 1 0 8 1 0
Italian 13 12 1 0 12 1 0
French 7 7 0 0 7 0 0
South American 2 2 0 0 2 0 0
Indian
Thai 2 2 0 0 2 0 0
Oriental 2 2 0 0 2 0 0
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uals heterozygous for Ile at position 313 are also heterozygous
for Asp at position 288. In the 1000 Genomes study, the fre-
quency of the allele with Asp-288 and Ile-313 is highest in Afri-
can populations (19%), intermediate in the Asian populations
(12%), and lowest in European and American populations
(6%).
Changes in Langerin Glycan Specificity Resulting from the
K313I Polymorphism—Residue 288 is near the principal Ca2
site to which the sugar binds, and the previous analysis shows
that the N288D change reduces sugar binding affinity (22).
Thus, langerin with both Asp-288 and Ile-313 was predicted to
have reduced affinity for all ligands as well as impaired 6SO4-
Gal binding activity. Glycan array screening was used to deter-
mine the effects of the K313I and N288D amino acid changes
on specificity of langerin for glycan ligands. A version of the
truncated, trimeric langerin mimicking the naturally occurring
minor allele with Asn-288 mutated to aspartate and Lys-313
changed to isoleucine (langerin-D288/I313) was created and
compared with the form with only the K313I change (langerin-
I313) and wild type langerin. Previous glycan array analysis of
langerin was carried out using version 3.2 of the glycan array of
the Consortium for Functional Glycomics (15). Here, version
5.0 of the glycan array, which is an expanded array containing
611 glycans, was screened.
In agreement with previous glycan array screening, wild type
langerin is seen to bind to high mannose structures (glycans
215, 316, and 317), some blood group A- or B-containing gly-
cans (glycans 91 and 109), and glycans with terminal 6SO4-Gal,
including glycans 298, 444, 445, 44, and 45, but not to other
types of sulfated glycans (Fig. 4) (15). Glycan array analysis of lan-
gerin with isoleucine at position 313 shows that binding to 6SO4-
Gal-terminated glycans is abolished by this amino acid change
because none of the ligands with terminal 6SO4-Gal that bind to
wild type langerinareboundby langerin-I313 (Fig. 4).This result is
consistentwith the large reduction in affinity for 6SO4-Gal caused
by the loss of lysine at position 313. In contrast, binding to high
mannose structures and fucosylated blood group antigens is unaf-
fected (Fig. 4) because binding of langerin-I313 to blood group A-
or B-containing glycans (glycans 91 and 109) and high mannose
structures (glycans 215, 316, and 317) is similar to that ofwild type
langerin. Interestingly, langerin-I313 shows enhanced binding of
many GlcNAc-terminated glycans, for example glycans 536, 584,
547, 177, 179, and531, as comparedwithwild type langerin,which
binds only weakly to these glycans.
FIGURE4.Glycanarrayanalysisof langerinvariants.Ligandsgiving thehighest signals are identified.Glycansaregroupedbasedonsimilar structures.Purple
indicates sulfated glycans, green indicates structures with terminal mannose residues, red denotes glycans containing the blood group A or B trisaccharides,
and GlcNAc-terminated glycans are indicated in blue. The complete list of glycans included in the figure is provided in supplemental Table 1.
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Screening of the glycan arraywith langerin-D288/I313 shows
that this form of langerin has similar specificity to langerin-
I313, with no binding to glycans with terminal 6SO4-Gal resi-
dues and enhanced binding to GlcNAc-terminated glycans
(Fig. 4). However, this form of langerin shows much weaker
binding of the fucosylated blood group antigens and high man-
nose structures that are bound by wild type langerin and lan-
gerin-I313. The results shown for langerin-D288/I313 are from
a screen performed in the presence of 20 mM CaCl2. Under the
usual screening conditions of 2mMCaCl2, the signals are lower,
although the pattern of ligands bound is similar, with most sig-
nificant binding to the GlcNAc-terminated ligands (data not
shown). These results are consistent with previous experiments
showing that the change of Asn-288 to aspartate results in a
decrease in the affinity of the carbohydrate recognition domain
for Ca2 and thus a decrease in sugar binding affinity (22).
Comparison of the glycan array results for langerin-D288/I313
and langerin-I313 indicates that the change of lysine to isoleu-
cine at position 313 results in altered specificity for glycan
ligands, from 6SO4-Gal- to GlcNAc-terminated glycans,
whereas the N288D change decreases the affinity for glycans.
Structural Basis for Enhanced Binding of GlcNAc—To deter-
mine the molecular basis for the enhanced binding of GlcNAc-
terminated glycans caused by theK313I change, crystal structures
of the carbohydrate recognition domains of langerin-I313, lan-
gerin-D288/I313, andwild type langerin in complexwithGlcNAc,
-Me-GlcNAc, and two GlcNAc-terminated trisaccharides
(GlcNAc1-3Gal1-4Glc-CH2CH2N3 (TR54) and GlcNAc1-
3Gal1-4GlcNAc-CH2CH2N3 (TR55)), representing the termi-
nalportionsofpolyN-acetyllactosaminechains thatare ligands for
langerindetectedon the glycan array,were solved. Because several
of the structures show the same interactions, to simplify presenta-
tion of the results, only the data sets that gave the highest resolu-
tion structures are shown: wild type langerin CRD bound to
-Me-GlcNAcand trisaccharideTR54, langerin-I313CRDbound
to -Me-GlcNAc and trisaccharide TR54, and langerin-D288/
I313 CRD bound to -Me-GlcNAc, -Me-Man and trisaccharide
TR55 (Tables 3 and 4).
The position of -Me-GlcNAc bound to the CRD of lan-
gerin-I313 (Fig. 5, A–C), is analogous the position of mannose
in the wild type CRD described previously (18). The 3- and
4-OHgroups of the sugar are coordinated to the principal Ca2
and form hydrogen bonds with Glu-293 and Asn-307 and with
Asn-287 and Glu-285, respectively. However, the equatorial
N-acetyl substituent at the two position of GlcNAc makes sev-
eral additional secondary contacts, including water-mediated
hydrogen bonds with Lys-299 and Asn-297. In addition, there
are van der Waals contacts with Pro-310, which in turn inter-
acts with Ile-313 (Fig. 5D). An alternate rotamer of the Ile-313
side chain brings it into direct van der Waals contact with the
N-acetyl group of theGlcNAc (Fig. 5E). A similar set of contacts
is seen in the structure of-Me-GlcNAc bound to the wild type
CRD, with the side chain of Lys-313 taking the place of the
isoleucine side chain (Fig. 5F). However, the Lys-313 side chain
has weak electron density, suggesting flexibility. Modeling
shows that some Lys-313 rotamers would occlude the sugar-
binding site, and in the absence of the intervening sulfate moi-
ety that is present in 6SO4-Gal, there might be electrostatic TA
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repulsion between Lys-313 and Lys-299. One or more of these
factors may explain the increased binding of the Ile-313 variant
to GlcNAc.
In the structures of the Ile-313 variant bound to a
GlcNAc-terminating trisaccharide, most of the glycan projects
away from the surface of the CRD (Fig. 6, A and B). Although
the position of the oligosaccharide is well defined in the elec-
tron density map (Fig. 6C), there are differences in the position
of the oligosaccharide in the different copies in the crystallo-
graphic asymmetric unit (Fig. 6D), probably resulting from
crystal contacts. This observation suggests that there may be
alternative orientations of the residues beyond the GlcNAc.
However, in all the observed orientations, there are hydrogen
bonds between the subterminal galactose residue and the side
chain of Lys-299 (Fig. 6, E and F). These contacts would not be
affected by the variations at positions 288 or 313.
Structures of the double mutant, with Asp-288 as well as
Ile-313, with -Me-GlcNAc, and with the extended GlcNAc-
containing oligosaccharides, showed exactly the same pattern
of interactions of the N-acetyl group as were observed for the
Ile-313 mutation alone. Thus, the differences in the interac-
tions of Lys-313 and Ile-313 described for the single sitemutant
can account for the enhanced binding of GlcNAc to the natu-
rally occurring Asp-288/Ile-313 variant as compared with the
wild type CRD.
To investigate the structural basis for the reduced binding of
mannose-containing structures to the Asp-288/Ile-313 variant,
the structure of this form of the CRD in complex with -Me-
Manwas determined (Fig. 7,A andB). The interactions ofman-
nose with the principal Ca2 through the 3- and 4-OH groups,
as well as the additional interaction of the 2-OH group with the
side chain of Lys-299, are the same as those observed for the
TABLE 4
Crystallographic refinement statistics
Langerin CRD
Me-GlcNAc
Langerin
CRD TR54
Langerin
CRD-I313
Me-GlcNAc
Langerin
CRD-I313
TR54
Langerin
CRD-D288/
I131Me-GlcNAc
Langerin
CRD-D288/
I131Me-Man
Langerin
CRD-D288/
I131 TR55
Number of reflections
used for refinement
53,793 44,431 53,381 45,546 44,894 36,132 35,498
Reflections marked for Rfree 2887 2366 2858 2438 2407 1908 1876
Rfreea 23.3 21.8 22.8 21.2 21.4 24.6 23.3
Rcrysta 18.0 17.3 17.6 16.6 17.0 18.9 18.1
Average B factor (Å2) 25.2 23.3 22.2 22.5 21.7 23.0 28.2
Bond length r.m.s.d.b (Å) 0.007 0.008 0.007 0.007 0.007 0.006 0.008
Angle r.m.s.d.b (°) 1.1 1.1 1.1 1.1 1.1 0.94 1.1
Ramachandran plot: (% in
each region)c
Preferred 96.0 96.2 95.8 95.8 95.4 96.0 95.0
Allowed 4.0 3.8 4.2 4.2 4.6 3.8 5.0
Outliers 0 0 0 0 0.0 0.2 0.0
aR and Rfree  Fo  Fc/Fo, where Fo  observed structure factor amplitude and Fc  calculated structure factor amplitude for the working and test sets,
respectively.
b r.m.s.d., root mean square deviation.
c As defined in Coot.
FIGURE5.Structuresof langerinCRDsbound to-Me-GlcNAc.A, overall viewof-Me-GlcNAcbound to theCRDportionof Langerin-I313.B, Fo Fc electron
density for the Me-GlcNAc bound to Langerin-I313, calculated by omitting the sugar residue from the model, contoured at 3.5 . C, interactions of
-Me-GlcNAc at the principal Ca2 site of Langerin-I313. D, interactions of the N-acetyl substituent of -Me-GlcNAc bound to Langerin-I313. E, interactions of
the N-acetyl substituent with an alternative rotamer of Ile-313. This rotamer is seen in one of four monomers in the crystals of langerin-I313 complexed with
-Me-GlcNAc and in two of four monomers in the crystals of langerin-I313 complexed with trisaccharide TR54 and langerin-D288/I313 complexed with
trisaccharide TR55. F, an equivalent view of Me-GlcNAc bound to the CRD from wild type langerin. Ca2 is shown in orange, oxygen atoms are red, and
nitrogen atoms are blue. Hydrogen bonds and van der Waals contacts were assigned withmaximum distance cutoffs of 3.4 and 4.2 Å, respectively. Hydrogen
bonds, coordination bonds, and van der Waals contacts are indicated by dotted lines.
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wild type CRD (18). The Ile-313 side chain is distant from the
mannose, consistent with the conclusion that this residue
enhances binding to GlcNAc but plays little role in the affinity
formannose because theAsp-288mutant alone shows a similar
loss of affinity. Residue 288 ismuch closer to the principal Ca2
site (Fig. 7, C and D). The position of the side chain of Lys-257
remains the same in the presence of either aspartic acid or
asparagine at position 288, and it does not have appropriate
geometry to form hydrogen bonds with the side chain at posi-
tion 288. However, the electrostatic interactions would be sig-
nificantly different with aspartic acid at position 288 because
this side chain forms a salt bridge with the amino group of
Lys-257, which in turn forms part of a water-mediated hydro-
gen bond network with the side chain of Asp-308 (Fig. 7C).
Interactions with both backbone and side chain oxygen atoms
of Asp-308 form a key part of the Ca2-binding site. Thus,
subtle differences in the hydrogen-bonding pattern resulting
from the change of asparagine to aspartic acid at this position,
could account for the reduced affinity for Ca2, which in turn
leads to an overall reduction in affinity for sugars (22).
DISCUSSION
The N288D and K313I polymorphisms in langerin provide
the first example of naturally occurring amino acid changes that
alter the glycan specificity of a glycan-binding receptor.Overall,
the combination of these two amino acid changes switches the
specificity of langerin from showing approximately equal bind-
ing to high mannose structures, fucosylated blood group anti-
gens, and glycans with terminal 6SO4-Gal, to bindingmainly to
glycans with terminal GlcNAc. The frequency of the allele con-
taining Asp-288 and Ile-313 is quite high; overall 1% of individ-
uals are homozygotes, and this value is higher in some African
populations. Individuals homozygous for the Asp-288/Ile-313
allele would produce langerin molecules that could not bind
glycans with terminal 6SO4-Gal. Because langerin functions as
a homotrimer, heterozygotes for the Asp-288/Ile-313 allele as
well as homozygotes would be expected to have langerin with
altered carbohydrate binding specificity. Assuming equal syn-
thesis of polypeptides from the two chromosomes and random
association of the polypeptides, in heterozygotes, only one in
eight langerin molecules would have three CRDs containing
Asn-288 and Lys-313 and one in eight langerin molecules
FIGURE 6.Structures of theCRDof langerin-I313bound toGlcNAc-1-3Gal1-4Glc.A, overall viewof the oligosaccharide-CRD complex. B, expanded view
of the oligosaccharide interactions at the principal Ca2 site. C, Fo  Fc electron density for the bound oligosaccharide, calculated by omitting the sugar
residues from the model, contoured at 3.0 . D, superposition of the bound oligosaccharide in copy A (yellow) and D (gray). E, view of oligosaccharide bound
to monomer A, showing interactions of the protein with the galactose residue. F, view of oligosaccharide bound to copy D. Ca2 is shown in orange, oxygen
atoms are red, and nitrogen atoms are blue.
FIGURE 7. Structure of the CRD of langerin-D288/I313. A, structure of lan-
gerin-D288/I313 CRD complexed with -Me-Man, showing the interactions
of the 3- and 4-OH groups with the principal Ca2. B, same structure as in A,
rotated to show additional interactions with the 2-OH group of mannose. C
andD, langerin-D288/I313CRD (C) andwild type langerin CRD (D) complexed
with -Me-GlcNAc, showing changes in the hydrogen bonds associated with
residue288as a result of theAsn/Asppolymorphism.Ca2 is shown inorange,
oxygen atoms are red, and nitrogen atoms are blue.
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would have three CRDs containing Asp-288 and Ile-313. The
remaining langerin trimers in heterozygotes would have two
CRDs with Asn-288 and Lys-313 and one with Asp-288 and
Ile-313 (three-eighths of the total langerin molecules) or one
CRD with Asn-288 and Lys-313 and two with Asp-288 and
Ile-313 (three-eighths of the total langerin molecules). Thus,
heterozygotes would potentially have langerin oligomers with a
range of differing carbohydrate specificities. Although the
effects of this range of specificities remain to be investigated,
having multiple types of binding sites might provide an advan-
tage in defense against a broad range of pathogens.
The physiological function of 6SO4-Gal binding by langerin
is not yet clear, although keratan sulfate is a potential endoge-
nous ligand containing 6SO4-Gal. Binding of langerin to kera-
tan sulfate from shark cartilage has been demonstrated, and
roles of langerin binding to keratan sulfate in cell adhesion or
tumor surveillance have been proposed (9). In the linear repeat-
ing Gal1-4GlcNAc1-3 structure of keratan sulfate, multiple
galactose residues as well as GlcNAc residues can be sulfated at
the 6-position (25). However, because binding of 6SO4-Gal to
the langerin CRD requires ligation of the 3- and 4-OH groups,
only 6SO4-Gal at the termini of keratan sulfate chains could
bind. The 3-OH groups of internal 6SO4-Gal residues are
linked to GlcNAc, preventing binding to langerin. The nonre-
ducing ends of keratan sulfate chains are often capped with
2-3-linked sialic acid, which would also prevent binding to
langerin. Langerinwas shown to bind toChinese hamster ovary
cells expressing large amounts of keratan sulfate following
transfection with both keratan sulfate 6-O sulfotransferase
(KS6GalST) and GlcNAc 6-O sulfotransferase (GlcNAc6ST),
the two enzymes that transfer sulfate to the 6-position of galac-
tose and GlcNAc, respectively (9). Binding was much greater if
the cells were first treated with a sialidase, consistent with the
presence of sialic acid capping groups preventing binding to
keratan sulfate. Langerin only binds to a glioblastoma cell line
expressing large amounts of keratan sulfate following sialidase
treatment, again emphasizing the fact that terminal 6SO4-Gal
residues on keratan are not common (9). In the same study,
langerin bound to mouse spleen cells without sialidase treat-
ment. Such binding could be due to the presence of 6SO4-Gal-
containing ligands because spleen expresses high levels of kera-
tan sulfate 6-O-sulfotransferase as comparedwith other tissues,
but highmannose or fucosylated glycans for langerin could also
have been present on the cells. Core 1 and Core 2 O-linked
glycans of mucins and mucin-like glycoproteins occasionally
have terminal 6SO4-Gal residues that would also be potential
endogenous ligands for langerin, although again most com-
monly 6SO4-Gal residues would be capped with 2-3-linked
sialic acid, preventing binding to langerin (26, 27).
It is possible that under certain pathological conditions,
undersialylation of glycans would leave more terminal 6SO4-
Gal exposed for recognition by langerin. There could also be
unique 6SO4-Gal-terminated glycans on specific proteins that
have not yet been identified. In the absence of a clear role for
6SO4-Gal recognition by langerin, it is difficult to predict the
effect that complete loss of this function might have. However,
what is currently known suggests that the 6SO4-Gal binding
activity of langerin could be dispensable, and individuals
homozygous for the Asp-288/Ile-313 form of langerin may not
be disadvantaged by loss of this activity.
The function of recognition of nonsulfated carbohydrate
ligands by langerin is clearer because these structures are found
on the surfaces of pathogens, and binding and uptake of several
microorganisms by langerin has been demonstrated. Langerin
binds viruses such as HIV and herpes simplex 2 through high
mannose structures present on envelope glycoproteins and can
also bind 1-2-linked mannose residues present in the man-
nans of fungal cell walls and on bacterial lipopolysaccharides (5,
6, 8, 9, 18). The fucosylated blood group B and A trisaccharides
recognized by langerin are also found on pathogenic bacteria,
such as Helicobacter pylori and Escherichia coli (28). GlcNAc
residues are also common on the surfaces of microorganisms,
on the lipopolysaccharides of Gram-negative bacteria and the
teichoic acids characteristic of Gram-positive bacteria, as well
as in chitin in the cell walls of fungi (29).
The linkage of the two polymorphisms in langerin may pro-
vide insight into co-evolution with pathogens. The D288N
change affects the stability of the primary binding site and
reduces the affinity of the CRD for monosaccharides. If this
mutation arose first, the change of Lys-313 to Ile may have
arisen subsequently in langerin with Asp-288 so that the pack-
ing interaction of the Ile side chain with the N-acetyl group of
GlcNAc could compensate for reduced affinity at the Ca2 site
and allow recognition of pathogenic bacteria. Prevalence of
pathogenic bacterial strainswithmoreGlcNAc in their cell wall
lipopolysaccharides or teichoic acidsmay thenhave selected for
the Asp-288/Ile-313 langerin allele in some populations.
The enhanced affinity for GlcNAc caused by the K313I
change may be advantageous in allowing more efficient uptake
of certain pathogens. Heterozygotes for the Asp-288/Ile-313
allelewould have some langerinmoleculeswith enhanced affin-
ity for GlcNAc while retaining some langerin molecules with
higher affinity for highmannose structures and fucosylated gly-
cans as well as 6SO4-Gal binding activity, potentially allowing
protection against awider range ofmicroorganisms. In contrast
to some other C-type lectins involved in pathogen recognition
such as DC-SIGN, which show considerable structural and
functional divergence between species (30), langerin is well
conserved in mammalian species. The existence of common
natural variants within a species may represent an alternative
way of adapting to the challenge of different pathogens.
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